Fishman D A, Viscarello R R, Cass I, Schwartz P E
Division of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Gynecol Oncol. 1995 Apr;57(1):105-8. doi: 10.1006/gyno.1995.1105.
This is the first report to evaluate the effects of combination chemotherapy on HIV-1 surrogate markers in an HIV-1-infected patient with an advanced epithelial ovarian cancer. Cisplatin combined with cyclophosphamide was well-tolerated, without significant changes in the HIV-1 p24 antigen, neopterin, beta 2-microglobulin, and CD4 values. The patient demonstrated a chemical and clinical response to therapy, without evidence of opportunistic infection or severe neutropenia. During the 6-month period of observation, treatment with cisplatin and cyclophosphamide did not significantly increase the risk of HIV-1 disease progression.
这是首份评估联合化疗对一名晚期上皮性卵巢癌合并HIV-1感染患者的HIV-1替代标志物影响的报告。顺铂联合环磷酰胺耐受性良好，HIV-1 p24抗原、新蝶呤、β2-微球蛋白及CD4值无显著变化。该患者对治疗有化疗及临床反应，无机会性感染或严重中性粒细胞减少的证据。在6个月的观察期内，顺铂和环磷酰胺治疗未显著增加HIV-1疾病进展风险。
